The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $25.32 in the prior trading day, PTC Therapeutics Inc (NASDAQ: PTCT) closed at $25.97, up 2.57%. In other words, the price has increased by $2.57 from its previous closing price. On the day, 0.65 million shares were traded. PTCT stock price reached its highest trading level at $26.485 during the session, while it also had its lowest trading level at $25.18.
Ratios:
Our goal is to gain a better understanding of PTCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.97 and its Current Ratio is at 2.02.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $37.
Oppenheimer Upgraded its Perform to Outperform on October 30, 2023, while the target price for the stock was maintained at $165.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 19 ’24 when Klein Matthew B. sold 3,361 shares for $24.89 per share. The transaction valued at 83,669 led to the insider holds 225,807 shares of the business.
Klein Matthew B. sold 1,307 shares of PTCT for $32,851 on Apr 17 ’24. The CHIEF EXECUTIVE OFFICER now owns 229,168 shares after completing the transaction at $25.14 per share. On Apr 17 ’24, another insider, Pauwels Eric, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 787 shares for $25.14 each. As a result, the insider received 19,781 and left with 67,694 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 1989509760 and an Enterprise Value of 3341894656. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.12. Its current Enterprise Value per Revenue stands at 3.563 whereas that against EBITDA is -29.624.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.69, which has changed by -0.4927734 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $59.84, while it has fallen to a 52-week low of $17.53. The 50-Day Moving Average of the stock is -7.22%, while the 200-Day Moving Average is calculated to be -10.62%.
Shares Statistics:
The stock has traded on average 899.14K shares per day over the past 3-months and 1007430 shares per day over the last 10 days, according to various share statistics. A total of 75.71M shares are outstanding, with a floating share count of 73.71M. Insiders hold about 3.79% of the company’s shares, while institutions hold 110.36% stake in the company. Shares short for PTCT as of 1711584000 were 10259982 with a Short Ratio of 11.41, compared to 1709164800 on 11400951. Therefore, it implies a Short% of Shares Outstanding of 10259982 and a Short% of Float of 18.049999.
Earnings Estimates
PTC Therapeutics Inc (PTCT) is currently under the scrutiny of 13 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of $-1.24 for the current quarter, with a high estimate of $-0.56 and a low estimate of $-1.93, while EPS last year was $-1.88. The consensus estimate for the next quarter is $-1.53, with high estimates of $-1.06 and low estimates of $-2.66.
Analysts are recommending an EPS of between $-2.66 and $-8.45 for the fiscal current year, implying an average EPS of $-5.84. EPS for the following year is $-4.99, with 14 analysts recommending between $-1.95 and $-9.16.
Revenue Estimates
10 analysts predict $170.21M in revenue for the current quarter. It ranges from a high estimate of $209.6M to a low estimate of $143.5M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $220.38M, an estimated decrease of -22.80% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $148.67M, a decrease of -30.50% less than the figure of $-22.80% in the same quarter last year. There is a high estimate of $169.37M for the next quarter, whereas the lowest estimate is $134.44M.
A total of 13 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $675.8M, while the lowest revenue estimate was $469.7M, resulting in an average revenue estimate of $605.22M. In the same quarter a year ago, actual revenue was $937.82M, down -35.50% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $618.36M in the next fiscal year. The high estimate is $747.97M and the low estimate is $332.8M. The average revenue growth estimate for next year is up 2.20% from the average revenue estimate for this year.
